x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Israel | Not applicable | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification no.) | |
3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel | 2069203 | |
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer o | Accelerated filer x |
Non-accelerated filer o | Smaller reporting company o |
(Do not check if a smaller reporting company) | Emerging growth company x |
Page No. | ||
March 31, | December 31, | ||||||
2017 | 2016 | ||||||
ASSETS | |||||||
CURRENT ASSETS | |||||||
Cash and cash equivalents | $ | 17,128 | $ | 23,678 | |||
Trade receivable, net | 1,401 | 1,254 | |||||
Prepaid expenses and other current assets | 1,361 | 1,291 | |||||
Inventory | 3,047 | 3,264 | |||||
Total current assets | 22,937 | 29,487 | |||||
LONG-TERM ASSETS | |||||||
Other long term assets | 1,220 | 1,018 | |||||
Property and equipment, net | 1,117 | 1,258 | |||||
Total long-term assets | 2,337 | 2,276 | |||||
Total assets | $ | 25,274 | $ | 31,763 |
March 31, | December 31, | ||||||
2017 | 2016 | ||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
CURRENT LIABILITIES | |||||||
Current maturities of long term loan | $ | 8,386 | $ | 7,495 | |||
Trade payables | 2,986 | 3,424 | |||||
Employees and payroll accruals | 706 | 1,019 | |||||
Deferred revenues and customers advances | 132 | 54 | |||||
Other current liabilities | 625 | 406 | |||||
Total current liabilities | 12,835 | 12,398 | |||||
LONG-TERM LIABILITIES | |||||||
Long term loan, net of current maturities | 8,492 | 10,518 | |||||
Deferred revenues | 333 | 284 | |||||
Other long-term liabilities | 272 | 303 | |||||
Total long-term liabilities | 9,097 | 11,105 | |||||
Total liabilities | 21,932 | 23,503 | |||||
COMMITMENTS AND CONTINGENT LIABILITIES | |||||||
Shareholders’ equity: | |||||||
Share capital | |||||||
Ordinary shares, par value NIS 0.01 per share-Authorized: 250,000,000 shares at March 31, 2017 and December 31, 2016; Issued and outstanding: 16,672,531 and 16,338,257 shares at March 31, 2017 and December 31, 2016, respectively | 46 | 45 | |||||
Additional paid-in capital | 116,199 | 114,707 | |||||
Accumulated deficit | (112,903 | ) | (106,492 | ) | |||
Total shareholders’ equity | 3,342 | 8,260 | |||||
Total liabilities and shareholders’ equity | $ | 25,274 | $ | 31,763 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Revenues | $ | 2,499 | $ | 2,061 | |||
Cost of revenues | 1,450 | 1,568 | |||||
Gross profit | 1,049 | 493 | |||||
Operating expenses: | |||||||
Research and development, net | 1,430 | 1,695 | |||||
Sales and marketing | 3,133 | 3,299 | |||||
General and administrative | 2,141 | 1,914 | |||||
Total operating expenses | 6,704 | 6,908 | |||||
Operating loss | (5,655 | ) | (6,415 | ) | |||
Financial expenses, net | 731 | 489 | |||||
Loss before income taxes | (6,386 | ) | (6,904 | ) | |||
Income taxes | 14 | 18 | |||||
Net loss | $ | (6,400 | ) | $ | (6,922 | ) | |
Net loss per ordinary share, basic and diluted | $ | (0.39 | ) | $ | (0.56 | ) | |
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted | 16,455,257 | 12,323,794 |
Ordinary Share | Additional paid-in capital | Accumulated deficit | Total shareholders’ equity | |||||||||||
Number | Amount | |||||||||||||
Balance as of January 1, 2016 | 12,222,583 | 33 | 94,876 | (73,989 | ) | 20,920 | ||||||||
Share-based compensation to employees and non-employees | — | — | 3,398 | — | 3,398 | |||||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees | 128,496 | 1 | 17 | — | 18 | |||||||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $468 | 692,062 | 2 | 4,097 | — | 4,099 | |||||||||
Issuance of warrants to purchase ordinary shares | — | — | 1,239 | — | 1,239 | |||||||||
Cashless exercise of warrants into ordinary shares | 45,116 | *) | *) | — | — | |||||||||
Issuance of ordinary shares and warrants to purchase ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,099 | 3,250,000 | 9 | 11,080 | — | 11,089 | |||||||||
Net loss | — | — | — | (32,503 | ) | (32,503 | ) | |||||||
Balance as of December 31, 2016 | 16,338,257 | 45 | 114,707 | (106,492 | ) | 8,260 | ||||||||
Cumulative effect to stock based compensation from adoption of a new accounting standard | — | — | 11 | (11 | ) | — | ||||||||
Share-based compensation to employees and non-employees | — | — | 851 | — | 851 | |||||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees | 26,807 | *) | 20 | — | 20 | |||||||||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $88 (1) | 307,467 | 1 | 610 | 611 | ||||||||||
Net loss | — | — | — | (6,400 | ) | (6,400 | ) | |||||||
Balance as of March 31, 2017 | 16,672,531 | 46 | 116,199 | (112,903 | ) | 3,342 |
*) | Represents an amount lower than $1. |
(1) | See Note 7e to the condensed consolidated financial statements |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Cash flows from operating activities: | |||||||
Net loss | $ | (6,400 | ) | $ | (6,922 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation | 180 | 163 | |||||
Share-based compensation to employees and non- employees | 851 | 717 | |||||
Deferred taxes | (47 | ) | (13 | ) | |||
Financial expenses related to long term loan | 33 | 156 | |||||
Changes in assets and liabilities: | |||||||
Trade receivables, net | (147 | ) | (295 | ) | |||
Prepaid expenses and other current and long term assets | (225 | ) | (607 | ) | |||
Inventories | 188 | (526 | ) | ||||
Trade payables | (438 | ) | 378 | ||||
Employees and payroll accruals | (313 | ) | (82 | ) | |||
Deferred revenues and advances from customers | 127 | 44 | |||||
Other current and long term liabilities | 141 | 50 | |||||
Net cash used in operating activities | (6,050 | ) | (6,937 | ) | |||
Cash flows from investing activities: | |||||||
Purchase of property and equipment | (10 | ) | (129 | ) | |||
Net cash used in investing activities | (10 | ) | (129 | ) | |||
Cash flows from financing activities: | |||||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non employees | 20 | — | |||||
Proceeds from long term loan | — | 12,000 | |||||
Debt issuance cost | — | (441 | ) | ||||
Repayment of long term loan | (1,168 | ) | (553 | ) | |||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $41 (1) | 658 | — | |||||
Net cash provided by (used in) financing activities | (490 | ) | 11,006 | ||||
Increase (decrease) in cash and cash equivalents | (6,550 | ) | 3,940 | ||||
Cash and cash equivalents at beginning of period | 23,678 | 17,869 | |||||
Cash and cash equivalents at end of period | $ | 17,128 | $ | 21,809 | |||
Supplemental disclosures of non-cash flow information | |||||||
At-the-market offering expenses not yet paid | $ | 47 | $ | — | |||
Issuance of ordinary shares upon exercise of stock options by employees and non-employees | $ | — | $ | 38 | |||
Classification of inventory to property and equipment, net | $ | 29 | $ | — |
a. | ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. |
b. | RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc., incorporated under the laws of Delaware on February 15, 2012, and (ii) ReWalk Robotics GMBH. incorporated under the laws of Germany on January 14, 2013. |
c. | During the three months ended March 31, 2017, the Company issued and sold 307,467 ordinary shares at an average price of $2.27 per share under its ATM Offering Program (as defined in Note 7e below). The gross proceeds to the Company were $699 thousand, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $88 thousand were $611 thousand. As a result, from the inception of the ATM Offering Program in May 2016 until March 31, 2017, the Company has issued and sold 999,529 ordinary shares at an average price of $5.27 per share under its ATM Offering Program, with gross proceeds of $5.3 million, and net aggregate proceeds of $4.7 million after deducting commissions, fees and offering expenses in the amount of $556 thousand. The Company could raise up to $25 million under its ATM Offering Program. See Note 7e below for more information about the Company’s ATM Offering Program. |
d. | The Company depends on one contract manufacturer. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. This vendor accounted for 0% and 12% of the Company's total trade payables as of March 31, 2017 and December 31, 2016, respectively. |
e. | On January 9, 2017, the Company announced its plan to reduce total operating expenses in 2017 by up to 30% as compared to 2016. These reductions will be achieved through a combination of targeted savings, including the completion of specific projects focused on quality improvement initiatives and efforts to reduce overall product cost, a realignment of and reduction in staffing to match the Company’s 2017 business goals, and a reduction in other corporate spending. |
f. | The Company has an accumulated deficit in the total amount of $113 million as of March 31, 2017 and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. |
a. | The significant accounting policies applied in the audited consolidated financial statements of the Company as disclosed in the Company's annual report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 17, 2017, as amended on Form 10-K/A filed with the SEC on April 27, 2017 (the “2016 Form 10-K”), are applied consistently in these unaudited interim condensed consolidated financial statements. |
b. | Recent Accounting Pronouncements: |
c. | Concentrations of Credit Risks: |
d. | Warranty provision |
US Dollars in thousands | |||
Balance at December 31, 2016 | $ | 498 | |
Provision | 117 | ||
Usage | (88 | ) | |
Balance at March 31, 2017 | $ | 527 |
March 31, | December 31, | ||||||
2017 | 2016 | ||||||
Finished products | 3,047 | 3,264 | |||||
$ | 3,047 | $ | 3,264 |
a. | Purchase commitments: |
b. | Royalties: |
c. | Liens: |
d. | Legal Claims: |
• | Dismissed Actions: |
◦ | On September 20, November 3, November 9, and November 10, 2016, respectively, four putative class actions on behalf of alleged shareholders that purchased or acquired the Company's ordinary shares pursuant and/or traceable to the registration statement used in connection with the Company's IPO were commenced in the Superior Court of the State of California, County of San Mateo. The actions were filed against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. We refer to these actions as the California State Actions. The complaints in the California State Actions asserted various claims under the Securities Act. Each of the California State Actions was dismissed for lack of personal jurisdiction in January 2017. |
◦ | On January 24, 2017, a substantially similar class action was commenced in the United States District Court for the Northern District of California (Case No. 4:17-cv-362) against the same defendants as in the California State Actions plus two “Secondary Offering Defendants” and four “Venture Capital Defendants,” entities that the complaint alleged to have beneficially owned, directly or indirectly, approximately 51% of the Company’s stock upon the closing of the IPO. This action alleged claims under Section 11 of the Securities Act against all defendants, Section 12 of the Securities Act against all defendants except the Venture Capital Defendants, and Section 15 of the Securities Act against all defendants except the Underwriter Defendants. This action is referred to as the California Federal Court Action. On March 23, 2017, this case was voluntarily dismissed. |
• | Pending Actions: |
◦ | On or about October 31, 2016, a class action with claims substantially similar to the California State Actions was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3336), alleging claims under Section 11 of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against the Company and certain of the Company's current and former directors and officers. |
◦ | On or about November 30, 2016, a substantially similar class action was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3670) alleging claims under Sections 11 and Section 15 of the Securities Act against the same defendants as in the action commenced on October 31, 2016, and also alleging claims under Section 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. This action was ordered consolidated in the Massachusetts Superior Court, Suffolk County on January 9, 2017 with the action commenced on October 31, 2016, and the two actions are referred to as the “Consolidated Massachusetts State Court Actions.” |
◦ | On or about January 31, 2017, a substantially similar class action was commenced in the United States District Court for the District of Massachusetts (Case No. 1:17-cv-10169) by four of the same plaintiffs who commenced the California State Court Actions, and two additional plaintiffs, alleging claims under Section 11 and 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against certain of the Company's current and former directors and officers. This action is referred to as the “Massachusetts Federal Court Action.” |
a. | Share option plans: |
Three Months Ended March 31, | ||
2016 | ||
Expected volatility | 60% | |
Risk-free rate | 1.43%-1.60% | |
Dividend yield | —% | |
Expected term (in years) | 5.31-6.11 | |
Share price | $8.48- $11.88 |
Three Months Ended March 31, 2017 | ||||||||||||
Number | Average exercise price | Average remaining contractual life (in years) (1) | Aggregate intrinsic value (in thousands) | |||||||||
Options and RSUs outstanding at the beginning of the period | 2,251,014 | $ | 6.47 | 7.80 | $ | 1,740 | ||||||
Options granted | — | — | ||||||||||
RSUs granted | — | — | ||||||||||
Options exercised (2) | (15,112 | ) | 1.43 | |||||||||
RSUs vested (2) | (7,363 | ) | — | |||||||||
RSUs forfeited | (24,534 | ) | — | |||||||||
Options forfeited | (58,894 | ) | 8.52 | |||||||||
Options and RSUs outstanding at the end of the period | 2,145,111 | $ | 6.54 | 7.36 | $ | 953 | ||||||
Options exercisable at the end of the period | 1,081,735 | $ | 5.57 | 6.47 | $ | 495 |
(1) | Calculation of weighted average remaining contractual term does not include RSUs, which have an indefinite contractual term. |
(2) | During the three month period ended March 31, 2017, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 22,475 ordinary shares. |
Range of exercise price | Options and RSUs outstanding as of March 31, 2017 | Weighted average remaining contractual life (years) (1) | Options exercisable as of March 31, 2017 | Weighted average remaining contractual life (years) (1) | ||||||||
RSUs only | 194,702 | — | — | — | ||||||||
$0.82 | 34,377 | 3.79 | 34,377 | 3.79 | ||||||||
$1.32 | 336,905 | 5.10 | 334,997 | 5.09 | ||||||||
$1.48 | 384,323 | 6.42 | 307,132 | 6.46 | ||||||||
$6.80- $8.99 | 720,618 | 8.49 | 240,800 | 8.03 | ||||||||
$9.22- $10.98 | 220,056 | 9.11 | 14,558 | 9.03 | ||||||||
$19.62-$20.97 | 254,130 | 7.54 | 149,871 | 7.41 | ||||||||
2,145,111 | 7.36 | 1,081,735 | 6.47 |
(1) | Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. |
b. | Share-based awards to non-employee consultants: |
c. | Warrants to purchase ordinary shares: |
Issuance date | Warrants outstanding | Exercise price per warrant | Warrants exercisable | Contractual term | |||||||
(number) | (number) | ||||||||||
July 14, 2014 (1) | 403,804 | $ | 10.08 | 403,804 | July 13, 2018 | ||||||
December 30, 2015 (2) | 119,295 | $ | 9.64 | 119,295 | See footnote (2) | ||||||
November 1, 2016 (3) | 2,437,500 | $ | 4.75 | 2,437,500 | November 1, 2021 | ||||||
December 28, 2016 (4) | 47,717 | $ | 9.64 | 47,717 | See footnote (4) | ||||||
3,008,316 | 3,008,316 |
d. | Share-based compensation expense for employees and non-employees: |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Cost of revenues | $ | 28 | $ | 22 | |||
Research and development, net | 113 | 113 | |||||
Sales and marketing, net | 185 | 174 | |||||
General and administrative | 525 | 408 | |||||
Total | $ | 851 | $ | 717 |
e. | At-the-market offering program: |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Foreign currency transactions and other | $ | (19 | ) | $ | 19 | ||
Financial expenses related to loan agreement with Kreos | 739 | 479 | |||||
Bank commissions | 11 | 9 | |||||
Income related to hedging transactions | — | (18 | ) | ||||
$ | 731 | $ | 489 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Revenues based on customer’s location : | |||||||
Israel | $ | — | $ | — | |||
United States | 2,099 | 1,739 | |||||
Europe | 400 | 260 | |||||
Asia-Pacific | — | 62 | |||||
Total revenues | $ | 2,499 | $ | 2,061 |
March 31, | December 31, | ||||||
2017 | 2016 | ||||||
Long-lived assets by geographic region (*): | |||||||
Israel | $ | 426 | $ | 476 | |||
United States | 498 | 565 | |||||
Germany | 193 | 217 | |||||
$ | 1,117 | $ | 1,258 |
March 31, | December 31, | ||||
2017 | 2016 | ||||
Customer A | 61 | % | 33 | % |
• | our expectations regarding future growth, including our ability to increase sales in our existing geographic markets expand to new markets and achieve our planned expense reductions; |
• | our management’s conclusion in the notes to our unaudited condensed consolidated financial statements included in this report and to our audited consolidated financial statements for fiscal 2016, and our independent registered public accounting firm’s statement in its opinion relating to our audited consolidated financial statements for fiscal 2016, that there is a substantial doubt as to our ability to continue as a going concern; |
• | our ability to maintain and grow our reputation and the market acceptance of our products; |
• | our ability to achieve reimbursement from third-party payors for our products; |
• | our expectations as to our clinical research program and clinical results; |
• | our expectations as to the results of and Food and Drug Administration’s, or the FDA’s, potential regulatory developments with respect to our mandatory 522 post-market surveillance study; |
• | the outcome of ongoing shareholder class action litigation relating to our initial public offering; |
• | our ability to repay our secured indebtedness; |
• | our ability to improve our products and develop new products; |
• | our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; |
• | our ability to gain and maintain regulatory approvals; |
• | our ability to secure capital from our at-the-market equity distribution program based on the price range of our ordinary shares and conditions in the financial markets; |
• | our ability to use effectively the proceeds of our follow-on public offering of ordinary shares and warrants; and, |
• | our ability to maintain relationships with existing customers and develop relationships with new customers. |
• | We placed 37 ReWalk devices during the quarter ended March 31, 2017, of which 26 were placed in the U.S. and 11 in Germany. |
• | 14 favorable case by case insurance reimbursement decisions were made. |
• | 28 units were ordered by the VA to support its national multi-center trial at VA facilities. |
• | We have set a target to reduce total operating expenses in 2017 by up to 30% as compared to 2016. These reductions will be achieved through a combination of targeted savings, including the completion of specific projects focused on quality improvement initiatives and efforts to reduce overall product cost, a realignment of and reduction in staffing to match the Company’s 2017 business goals, and a reduction in other corporate spending. |
• | During the quarter ended March 31, 2017, we sold 307,467 shares generating total net proceeds to the Company of $611 thousand (after commissions, fees and expenses) under our ATM Offering Program. For more information, see Note 7e to our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” above and “Liquidity and Capital Resources” below. |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
(in thousands, except per share data) | |||||||
Statements of Operations Data: | |||||||
Revenues | $ | 2,499 | $ | 2,061 | |||
Cost of revenues | 1,450 | 1,568 | |||||
Gross profit | 1,049 | 493 | |||||
Operating expenses: | |||||||
Research and development, net | 1,430 | 1,695 | |||||
Sales and marketing | 3,133 | 3,299 | |||||
General and administrative | 2,141 | 1,914 | |||||
Total operating expenses | 6,704 | 6,908 | |||||
Operating loss | (5,655 | ) | (6,415 | ) | |||
Financial expenses, net | 731 | 489 | |||||
Loss before income taxes | (6,386 | ) | (6,904 | ) | |||
Income taxes | 14 | 18 | |||||
Net loss | $ | (6,400 | ) | $ | (6,922 | ) | |
Net loss per ordinary share, basic and diluted | $ | (0.39 | ) | $ | (0.56 | ) | |
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted | 16,455,257 | 12,323,794 |
Three Months Ended March 31, | |||
2017 | 2016 | ||
(in thousands, except unit amounts) | |||
Personal units placed | 36 | 31 | |
Rehabilitation units placed | 1 | 1 | |
Total units placed | 37 | 32 | |
Personal unit revenues | $2,423 | $1,971 | |
Rehabilitation unit revenues | $76 | $90 | |
Revenues | $2,499 | $2,061 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Gross profit | $ | 1,049 | $ | 493 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Research and development expenses, net | $ | 1,430 | $ | 1,695 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Sales and marketing expenses | $ | 3,133 | $ | 3,299 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
General and administrative | $ | 2,141 | $ | 1,914 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Financial expenses, net | $ | 731 | $ | 489 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Income tax | $ | 14 | $ | 18 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Net cash used in operating activities | $ | (6,050 | ) | $ | (6,937 | ) | |
Net cash used in investing activities | (10 | ) | (129 | ) | |||
Net cash provided by (used in) financing activities | (490 | ) | 11,006 | ||||
Net cash flow | $ | (6,550 | ) | $ | 3,940 |
Payments due by period (in dollars, in thousands) | |||||||||||||||||||
Contractual obligations | Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years | ||||||||||||||
Purchase obligations (1) | $ | 1,464 | $ | 1,464 | $ | — | $ | — | $ | — | |||||||||
Collaboration Agreement and License Agreement obligations (2) | 5,442 | 1,929 | 2,250 | 1,263 | — | ||||||||||||||
Operating lease obligations (3) | 4,490 | 609 | 1,124 | 1,148 | 1,609 | ||||||||||||||
Long-term debt obligations (4) | 20,382 | 8,386 | 11,996 | — | — | ||||||||||||||
Total | $ | 31,778 | $ | 12,388 | $ | 15,370 | $ | 2,411 | $ | 1,609 |
Exhibit Number | Description | |
10.1 | Agreement and Release between ReWalk Robotics, Inc. and John Hamilton, dated as of January 24, 2017** | |
10.2 | Consultant Agreement between ReWalk Robotics, Inc. and John Hamilton, dated as of January 30, 2017** | |
31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002. | |
31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002. | |
32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | |
32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | |
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema Document | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
* | Furnished herewith. |
** | Management contract or compensatory plan, contract or arrangement. |
ReWalk Robotics Ltd. | ||
Date: May 4, 2017 | By: | /s/ Larry Jasinski |
Larry Jasinski | ||
Chief Executive Officer | ||
Date: May 4, 2017 | By: | /s/ Kevin Hershberger |
Kevin Hershberger | ||
Chief Financial Officer | ||
(Principal Financial and Accounting Officer) |
(b) | Employee has the option to elect to continue health and dental insurance coverage in accordance with the provisions of COBRA, or he may elect to enroll in health insurance coverage through an “Exchange” under the Affordable Care Act. Should Employee elect continuation of coverage either under COBRA or an Exchange, ReWalk will reimburse him in an amount equal to 100% of his health and dental insurance premium payment covering the period from January 27, 2017 through December 31, 2017 or the termination of his Consultant Agreement, whichever comes first. After such period, if Employee has elected COBRA coverage, such medical and dental insurance coverage shall be continued only to the extent required by COBRA and provided that he timely pays the full amount of each COBRA premium payment. If he has elected coverage via the Exchange, his coverage shall continue only to the extent he complies with the requirements set forth by the Exchange with respect to payment of premiums. |
/s/ Judy Kula | 1/24/2017 | /s/ John V. Hamilton | 1/24/2017 | |
Witness | Date | John V. Hamilton | Date |
/s/ Judy Kula | 1/24/2017 | /s/ Larry J. Jasinski | 1/24/2017 | |
Witness | Date | By: Lawrence J. Jasinski | Date |
/s/ Judy Kula | By: /s/ Larry J. Jasinski | ||
Witness | Larry J. Jasinski, CEO |
/s/ Judy Kula | /s/ John V. Hamilton | ||
Witness | John V. Hamilton |
/s/ Larry Jasinski | |
Larry Jasinski | |
Chief Executive Officer | |
(Principal Executive Officer) | |
ReWalk Robotics Ltd. |
/s/ Kevin Hershberger | |
Kevin Hershberger | |
Chief Financial Officer | |
(Principal Financial Officer) | |
ReWalk Robotics Ltd. |
• | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
• | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Larry Jasinski | |
Larry Jasinski | |
Chief Executive Officer | |
(Principal Executive Officer) | |
ReWalk Robotics Ltd. |
• | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
• | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Kevin Hershberger | |
Kevin Hershberger | |
Chief Financial Officer | |
(Principal Financial Officer) | |
ReWalk Robotics Ltd. |
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
May 01, 2017 |
|
Document and Entity Information [Abstract] | ||
Entity Registrant Name | ReWalk Robotics Ltd. | |
Entity Central Index Key | 0001607962 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 16,675,233 | |
Document Fiscal Year Focus | 2017 | |
Document Fiscal Period Focus | Q1 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Ordinary shares, par value (in ILS per share) | ₪ 0.01 | ₪ 0.01 |
Ordinary shares, shares authorized (in shares) | 250,000,000 | 250,000,000 |
Ordinary shares, shares Issued (in shares) | 16,672,531 | 16,338,257 |
Ordinary shares, shares outstanding (in shares) | 16,672,531 | 16,338,257 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Income Statement [Abstract] | ||
Revenues | $ 2,499 | $ 2,061 |
Cost of revenues | 1,450 | 1,568 |
Gross profit | 1,049 | 493 |
Operating expenses: | ||
Research and development, net | 1,430 | 1,695 |
Sales and marketing | 3,133 | 3,299 |
General and administrative | 2,141 | 1,914 |
Total operating expenses | 6,704 | 6,908 |
Operating loss | (5,655) | (6,415) |
Financial expenses, net | 731 | 489 |
Loss before income taxes | (6,386) | (6,904) |
Income taxes | 14 | 18 |
Net loss | $ (6,400) | $ (6,922) |
Net loss per ordinary share, basic and diluted (in USD per share) | $ (0.39) | $ (0.56) |
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (in shares) | 16,455,257 | 12,323,794 |
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) $ in Thousands |
12 Months Ended |
---|---|
Dec. 31, 2016
USD ($)
| |
ATM Offering Program | Ordinary Share | |
Issuance costs | $ 468 |
Follow On Public Offering | Ordinary Share | |
Issuance costs | $ 1,099 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|||
Cash flows from operating activities: | ||||
Net loss | $ (6,400) | $ (6,922) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation | 180 | 163 | ||
Share-based compensation to employees and non- employees | 851 | 717 | ||
Deferred taxes | (47) | (13) | ||
Financial expenses related to long term loan | 33 | 156 | ||
Changes in assets and liabilities: | ||||
Trade receivables, net | (147) | (295) | ||
Prepaid expenses and other current and long term assets | (225) | (607) | ||
Inventories | 188 | (526) | ||
Trade payables | (438) | 378 | ||
Employees and payroll accruals | (313) | (82) | ||
Deferred revenues and advances from customers | 127 | 44 | ||
Other current and long term liabilities | 141 | 50 | ||
Net cash used in operating activities | (6,050) | (6,937) | ||
Cash flows from investing activities: | ||||
Purchase of property and equipment | (10) | (129) | ||
Net cash used in investing activities | (10) | (129) | ||
Cash flows from financing activities: | ||||
Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non employees | 20 | 0 | ||
Proceeds from long term loan | 0 | 12,000 | ||
Debt issuance cost | 0 | (441) | ||
Repayment of long term loan | (1,168) | (553) | ||
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $41 | [1] | 658 | 0 | |
Net cash provided by (used in) financing activities | (490) | 11,006 | ||
Increase (decrease) in cash and cash equivalents | (6,550) | 3,940 | ||
Cash and cash equivalents at beginning of period | 23,678 | 17,869 | ||
Cash and cash equivalents at end of period | 17,128 | 21,809 | ||
Supplemental disclosures of non-cash flow information | ||||
At-the-market offering expenses not yet paid | 47 | 0 | ||
Issuance of ordinary shares upon exercise of stock options by employees and non-employees | 0 | 38 | ||
Classification of inventory to property and equipment, net | $ 29 | $ 0 | ||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2017
USD ($)
| |
Statement of Cash Flows [Abstract] | |
Issuance expenses | $ 41 |
GENERAL |
3 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||
GENERAL | GENERAL
The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, issuances under the Company's ATM Offering Program or other future issuances of equity and debt securities, or through a combination of the foregoing. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements for the three months ended March 31, 2017 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i)consolidated financial position as of March 31, 2017, (ii) consolidated results of operations for the three months ended March 31, 2017 and (iii) consolidated cash flows for the three months ended March 31, 2017. The results for the three months periods ended March 31, 2017, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. |
SIGNIFICANT ACCOUNTING POLICIES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
SIGNIFICANT ACCOUNTING POLICIES | SIGNIFICANT ACCOUNTING POLICIES
Recently Implemented Accounting Pronouncements Inventory - In July 2015, the FASB issued Accounting Standards Update 2015-11, “Simplifying the Measurement of Inventory.” The standard changes the inventory valuation method from the lower of cost or market to the lower of cost or net realizable value for inventory valued under the first-in, first-out or average cost methods. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods and requires prospective adoption with early adoption permitted. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Deferred Taxes - In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes", which simplifies the presentation of deferred income taxes. ASU 2015-17 provides presentation requirements to classify deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company elected to implement this ASU-2015-17 prospectively. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Recent Accounting Pronouncements Not Yet Adopted Revenues - In May 2014, the Financial Accounting Standards Board (the “FASB") issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In 2016, the FASB issued four amendments to ASU 2014-09. The standard is effective for public companies for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company has not selected an implementation approach. The Company elected not to adopt the standard early and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures. Leases - In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on the Company's consolidated financial statements and related disclosures. Statement of Cash Flows - In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company has not yet determined whether it will elect early adopt the standard and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures. Statement of Cash Flows - On November 17, 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force).” This ASU requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are to be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows. ASU No. 2016-18 will be effective for us as of January 1, 2018. The Company does not expect the adoption to have a material impact on the Company's consolidated financial statements.
Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. One customer represented 41% and 0% of the Company's trade receivable, net balance as of March 31, 2017 and December 31, 2016, respectively. As of March 31, 2017 and December 31, 2016 trade receivables are presented net of allowance for doubtful accounts in the amount of $324 thousand and $333 thousand, respectively and net of sales return reserve of $105 thousand as of March 31, 2017 and December 31, 2016.
The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
|
INVENTORY |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORY | INVENTORY The components of inventory are as follows (in thousands):
|
COMMITMENTS AND CONTINGENT LIABILITIES |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
COMMITMENTS AND CONTINGENT LIABILITIES | COMMITMENTS AND CONTINGENT LIABILITIES
The Company has contractual obligations to purchase goods from its contract manufacturer- Sanmina Corporation. Purchase obligations do not include contracts that may be canceled without penalty. As of March 31, 2017, non-cancelable outstanding obligations amounted to approximately $1.46 million.
The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority, or the IIA, (formerly known as the Israeli Office of the Chief Scientist in the Israel Ministry of Economy). During the three months ended March 31, 2017 the Company received $300 thousand from the IIA to fund its research and development efforts. Since the Company’s inception through March 31, 2017, the Company received funding from the IIA in the total amount of $1.0 million. Out of the $1.0 million in funding from the IIA, a total amount of $640 thousand were royalty bearing grants (as of March 31, 2017, the Company paid royalties to the IIA in the total amount of $50 thousand), while a total amount of $400 thousand was received in consideration of 5,237 convertible preferred A shares. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. As of March 31, 2017, the contingent liability to the IIA amounted to $590 thousand.
As discussed in Note 6 to our audited consolidated financial statements included in our 2016 Form 10-K, the Company is party to a loan agreement with Kreos pursuant to which Kreos extended a $20.0 million line of credit to the Company. In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company's other long-term assets in the amount of $841 thousand have been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.
Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses, and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As set forth below, between September 2016 and January 2017, eight substantially similar putative securities class actions were filed against the Company. Four of these actions have been dismissed on procedural grounds, one was voluntarily dismissed and three are pending, including two actions which have been consolidated and one action brought by the plaintiffs whose actions were dismissed.
The plaintiffs in the Consolidated Massachusetts State Court Actions filed a consolidated amended complaint on March 20, 2017. The Company has not yet responded to the complaints in the Consolidated Massachusetts State Court Action or the Massachusetts Federal Court Action. The complaints in all of the actions listed above allege that the Company's registration statement used in connection with its IPO failed to disclose that the Company was unprepared or unable to comply with certain regulatory special controls and to provide the FDA with a post-market surveillance study on the Company's ReWalk Personal device, and that, as a result of such alleged omission, the plaintiffs suffered damages. The Company believes that the allegations made in the complaints are without merit and intends to defend itself vigorously against the complaints relating to the three pending actions. Based on information currently available and the early stage of the litigation, the Company is unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to these lawsuits; therefore, no litigation reserve has been recorded in the Company's consolidated balance sheets as of March 31, 2017. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable. |
RESEARCH COLLABORATION AND LICENSE AGREEMENT |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Research and Development [Abstract] | |
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT | RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of March 31, 2017, the Company did not achieve any of these milestones, and is evaluating the likelihood that the milestones will be achieved on a quarterly basis. Moreover, since such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on the Company's condensed consolidated balance sheet as of March 31, 2017. The Company's total payment obligation under the Collaboration Agreement and of the License Agreement is $6.3 million, some of it is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expense in the amount of $306 thousand which is part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three months period ended March 31, 2017. |
SHAREHOLDERS' EQUITY |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SHAREHOLDERS' EQUITY | SHAREHOLDERS’ EQUITY
As of March 31, 2017, and December 31, 2016, the Company had reserved 1,116,612 and 380,153 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers and consultants pursuant to equity awards granted under the Company's 2014 Incentive Compensation Plan (the “2014 Plan”). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. There were no option grants during the three months ended March 31, 2017. The fair value for options granted during the three months ended March 31, 2016 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:
The fair value of restricted stock units (“RSUs”) granted is determined based on the price of the Company's ordinary shares on the date of grant. A summary of employee options to purchase ordinary shares and RSUs during the three months ended March 31, 2017 is as follows:
The weighted average grant date fair value of options granted during the three month period ended March 31, 2016 was $5.88. The Company did not grant options during the three months period ended March 31, 2017. The Company did not grant RSUs to any of its employees during the three month periods ended March 31, 2017 and March 31, 2016. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for each of the three months period ended March 31, 2017 and March 31, 2016 was $25 thousand and $786 thousand respectively. As of March 31, 2017, there were $6.3 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company's 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 2.2 years. The number of options and RSUs outstanding as of March 31, 2017 is set forth below, with options separated by range of exercise price.
The Company granted options to a non-employee consultant on March 12, 2007, which were exercised during the three months ended March 31, 2017. The Company granted 1,500 fully vested RSUs on January 1, 2017 to a non-employee consultant. As of March 31, 2017, there are no outstanding options or RSUs held by non-employee consultants.
The following table summarizes information about warrants outstanding and exercisable as of March 31, 2017:
(1) Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round. (2) Represents a warrant to purchase ordinary shares at an exercise price of $9.64 per share, which was issued on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us. The warrant is currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrant had been exercised as of March 31, 2017. (3) Represents warrants issued as part of our follow-on offering in November 2016. (4) Represents a warrant in the amount of 47,717 ordinary shares issued to Kreos as part of the $8.0 million drawdown under the Loan Agreement, which occurred on December 28, 2016. See footnote 2 for exercisability terms.
The Company recognized non-cash share-based compensation expense for both employees and non-employees in the consolidated statements of operations for the periods shown below as follows (in thousands):
On May 10, 2016, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's registration statement on Form S-3, which was declared effective on May 9, 2016 (the “Form S-3”), in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Offering Program”). Sales may be made directly on or through the NASDAQ Global Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time. During the three months ended March 31, 2017, the Company issued and sold 307,467 ordinary shares at an average price of $2.27 per share under its ATM Offering Program (as defined in Note 7e below). The gross proceeds to the Company were $699 thousand, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $88 thousand were $611 thousand. As a result, from the inception of the ATM Offering Program in May 2016 until March 31, 2017, the Company had sold 999,529 ordinary shares under the ATM Offering Program for gross proceeds of $5.3 million and net proceeds to the Company of $4.7 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation of $158 thousand and had incurred total expenses of approximately $556 thousand in connection with the ATM Offering Program. |
FINANCIAL EXPENSES, NET |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINANCIAL EXPENSES, NET | FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows (in thousands):
|
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA | GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing the enterprise’s performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 above of this quarterly report for a brief description of the Company’s business). The following is a summary of revenues within geographic areas (in thousands):
(*) Long-lived assets are comprised of property and equipment, net. Major customer data as a percentage of total revenues (in thousands):
|
SIGNIFICANT ACCOUNTING POLICIES (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting | The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company's (i)consolidated financial position as of March 31, 2017, (ii) consolidated results of operations for the three months ended March 31, 2017 and (iii) consolidated cash flows for the three months ended March 31, 2017. The results for the three months periods ended March 31, 2017, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements: Recently Implemented Accounting Pronouncements Inventory - In July 2015, the FASB issued Accounting Standards Update 2015-11, “Simplifying the Measurement of Inventory.” The standard changes the inventory valuation method from the lower of cost or market to the lower of cost or net realizable value for inventory valued under the first-in, first-out or average cost methods. This standard is effective for fiscal years beginning after December 15, 2016, including interim periods and requires prospective adoption with early adoption permitted. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Deferred Taxes - In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes", which simplifies the presentation of deferred income taxes. ASU 2015-17 provides presentation requirements to classify deferred tax assets and liabilities, along with any related valuation allowance, as noncurrent on the balance sheet. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within that reporting period. The Company elected to implement this ASU-2015-17 prospectively. The update was effective for the Company beginning January 1, 2017. The adoption of this standard did not materially impact the Company's financial statements. Recent Accounting Pronouncements Not Yet Adopted Revenues - In May 2014, the Financial Accounting Standards Board (the “FASB") issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In 2016, the FASB issued four amendments to ASU 2014-09. The standard is effective for public companies for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company has not selected an implementation approach. The Company elected not to adopt the standard early and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures. Leases - In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on the Company's consolidated financial statements and related disclosures. Statement of Cash Flows - In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company has not yet determined whether it will elect early adopt the standard and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures. Statement of Cash Flows - On November 17, 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force).” This ASU requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are to be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows. ASU No. 2016-18 will be effective for us as of January 1, 2018. The Company does not expect the adoption to have a material impact on the Company's consolidated financial statements. |
Concentrations of Credit Risks | Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. |
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||
Schedule of Product Warranty Liability | The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
|
INVENTORY (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of inventories | The components of inventory are as follows (in thousands):
|
SHAREHOLDERS' EQUITY (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of stock option valuation assumptions | The fair value for options granted during the three months ended March 31, 2016 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option and RSU activity | A summary of employee options to purchase ordinary shares and RSUs during the three months ended March 31, 2017 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of options and RSUs outstanding which have been separated into ranges of exercise price | The number of options and RSUs outstanding as of March 31, 2017 is set forth below, with options separated by range of exercise price.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of warrants outstanding and exercisable | The following table summarizes information about warrants outstanding and exercisable as of March 31, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of non-cash share-based compensation expense | The Company recognized non-cash share-based compensation expense for both employees and non-employees in the consolidated statements of operations for the periods shown below as follows (in thousands):
|
FINANCIAL EXPENSES, NET (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of financial expenses, net | The components of financial expenses, net were as follows (in thousands):
|
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of revenues within geographic areas | The following is a summary of revenues within geographic areas (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of long-lived assets by geographic region |
(*) Long-lived assets are comprised of property and equipment, net. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of major customer data as a percentage of total revenues | Major customer data as a percentage of total revenues (in thousands):
|
GENERAL (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2017
USD ($)
subsidiary
|
Dec. 31, 2017 |
Dec. 31, 2016
USD ($)
|
|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Number of wholly-owned subsidiaries | subsidiary | 2 | ||
Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Line Items] | |||
Accumulated deficit | $ | $ 112,903 | $ 106,492 | |
Maximum | Scenario, Forecast | |||
Effects on Future Earnings and Cash Flows Resulting from Exit Plan [Line Items] | |||
Expected reduction in operating expenses | 30.00% |
GENERAL - ATM Offering Program (Details) - USD ($) |
3 Months Ended | 11 Months Ended | 12 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
May 10, 2016 |
|||||
Class of Stock [Line Items] | ||||||||
Maximum amount which can be raised under ATM offering program | $ 25,000,000 | $ 25,000,000 | $ 25,000,000.0 | |||||
ATM Offering Program | ||||||||
Class of Stock [Line Items] | ||||||||
Gross proceeds from shares issued under the ATM offering program | 699,000 | 5,300,000 | ||||||
Underwriter commission, fees and offering expenses | 88,000 | 556,000 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | $ 611,000 | [1] | $ 4,700,000 | $ 4,099,000 | ||||
ATM Offering Program | Weighted Average | ||||||||
Class of Stock [Line Items] | ||||||||
Price per share of shares sold under ATM offering program (in USD per share) | $ 2.27 | $ 5.27 | ||||||
Ordinary Share | ATM Offering Program | ||||||||
Class of Stock [Line Items] | ||||||||
Issuance of ordinary shares in an offering, net of issuance expenses (in shares) | 307,467 | [1] | 999,529 | [1] | 692,062 | |||
Underwriter commission, fees and offering expenses | $ 88,000 | $ 468,000 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | $ 1,000 | [1] | $ 2,000 | |||||
|
GENERAL - Concentration Risk (Details) - Vendor concentration - Trade payables - manufacturer |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Concentration Risk [Line Items] | ||
Number of contract manufacturers | 1 | 1 |
Concentration risk (as a percent) | 0.00% | 12.00% |
SIGNIFICANT ACCOUNTING POLICIES (Concentrations of Credit Risks) (Details) $ in Thousands |
Mar. 31, 2017
USD ($)
customer
|
Dec. 31, 2016
USD ($)
customer
|
---|---|---|
Concentration Risk [Line Items] | ||
Allowance for doubtful accounts | $ 324 | $ 333 |
Sales return reserve | $ 105 | $ 105 |
Trade Receivable | Customer concentration | ||
Concentration Risk [Line Items] | ||
Number of customers | customer | 1 | 1 |
Concentration risk (as a percent) | 41.00% | 0.00% |
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES (Warranty Provision) (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2017
USD ($)
| |
Accounting Policies [Abstract] | |
Standard warranty term | 2 years |
Movement in Standard Product Warranty Accrual [Roll Forward] | |
Balance at December 31, 2016 | $ 498 |
Provision | 117 |
Usage | (88) |
Balance at March 31, 2017 | $ 527 |
INVENTORY (Details) - USD ($) $ in Thousands |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Finished products | $ 3,047 | $ 3,264 |
Inventories | $ 3,047 | $ 3,264 |
COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details) |
2 Months Ended | 3 Months Ended | 5 Months Ended | 8 Months Ended | 12 Months Ended | 189 Months Ended | |
---|---|---|---|---|---|---|---|
Jan. 24, 2017
action
|
Nov. 10, 2016
action
|
Mar. 31, 2017
USD ($)
|
Jan. 31, 2017
action
|
May 04, 2017
action
|
Dec. 31, 2016 |
Mar. 31, 2017
USD ($)
shares
|
|
Commitments and Contingencies Disclosure [Abstract] | |||||||
Outstanding purchase orders | $ 1,460,000 | $ 1,460,000 | |||||
Other Commitments [Line Items] | |||||||
Collateral pledged | 841,000 | ||||||
Number of putative class actions brought against the company | action | 4 | 8 | |||||
Actions dismissed | action | 1 | ||||||
Percentage of common stock owned by the plaintiffs | 51.00% | ||||||
Litigation reserve | 0 | 0 | |||||
Subsequent Event | |||||||
Other Commitments [Line Items] | |||||||
Actions dismissed | action | 4 | ||||||
Actions pending | action | 3 | ||||||
Subsequent Event | Consolidated Litigation | |||||||
Other Commitments [Line Items] | |||||||
Actions pending | action | 2 | ||||||
Subsequent Event | Plaintiff's Actions Dismissed | |||||||
Other Commitments [Line Items] | |||||||
Actions pending | action | 1 | ||||||
Term Loan | 10.75% Term Loan Due January 2019 | |||||||
Other Commitments [Line Items] | |||||||
Line of credit | 20,000,000.0 | 20,000,000.0 | |||||
IIA | |||||||
Other Commitments [Line Items] | |||||||
Total funding received | 300,000 | 1,000,000 | |||||
Royalty bearing grants | 640,000 | ||||||
Royalties paid | 50,000 | ||||||
Contingent liability | $ 590,000 | 590,000 | |||||
Series A Preferred Stock | IIA | |||||||
Other Commitments [Line Items] | |||||||
Amount received in consideration of preferred shares | $ 400,000 | ||||||
Issuance of ordinary shares (in shares) | shares | 5,237 | ||||||
Minimum | IIA | |||||||
Other Commitments [Line Items] | |||||||
Royalty (as a percent) | 3.00% | ||||||
Maximum | IIA | |||||||
Other Commitments [Line Items] | |||||||
Royalty (as a percent) | 3.50% | ||||||
Percentage of grant received considered to determine royalty fees | 100.00% |
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Research and development, net | $ 1,430 | $ 1,695 |
Collaboration and Licensing Agreement | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Total payment obligation | 6,300 | |
Research and development, net | $ 306 |
SHAREHOLDERS' EQUITY (Narrative - Share Option Plans) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Shareholders' equity (deficiency) [Line Items] | |||
Unrecognized compensation cost | $ 6,300 | ||
Period of recognition of unrecognized compensation cost | 2 years 2 months 12 days | ||
Options | |||
Shareholders' equity (deficiency) [Line Items] | |||
Shares reserved for future issuance (in shares) | 1,116,612 | 380,153 | |
Award vesting period | 4 years | ||
Weighted average grant date fair values, options (in USD per share) | $ 5.88 | ||
Total intrinsic value of options exercised | $ 25 | $ 786 | |
Options granted (in shares) | 0 | ||
Non-employee Director | Options | |||
Shareholders' equity (deficiency) [Line Items] | |||
Award vesting period | 1 year |
SHAREHOLDERS' EQUITY (Option Valuation Assumptions) (Details) |
3 Months Ended |
---|---|
Mar. 31, 2016
$ / shares
| |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected volatility | 60.00% |
Risk-free rate, minimum (as a percent) | 1.43% |
Risk-free rate, maximum (as a percent) | 1.60% |
Dividend yield | 0.00% |
Minimum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected term (in years) | 5 years 3 months 22 days |
Share price (in USD per share) | $ 8.48 |
Maximum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected term (in years) | 6 years 1 month 10 days |
Share price (in USD per share) | $ 11.88 |
SHAREHOLDERS' EQUITY (Summary of Employee Share Option and RSU Activity ) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2017 |
Dec. 31, 2016 |
|
Aggregate intrinsic value (in thousands) | ||
Issuance of ordinary share upon exercise of stock options and vesting of RSUs (in shares) | 22,475 | |
Stock Options and RSUs | ||
Number | ||
Options and RSU's outstanding at the beginning of the period (in shares) | 2,251,014 | |
Options and RSU's outstanding at the end of the period (in shares) | 2,145,111 | 2,251,014 |
Average exercise price | ||
Options and RSUs outstanding at the beginning of the period (in USD per share) | $ 6.47 | |
Options and RSUs outstanding at the end of the period (in USD per share) | $ 6.54 | $ 6.47 |
Average remaining contractual life (in years) | ||
Options and RSUs outstanding | 7 years 4 months 10 days | 7 years 9 months 18 days |
Aggregate intrinsic value (in thousands) | ||
Options and RSUs outstanding at beginning of the period | $ 1,740 | |
Options and RSUs outstanding at the end of the period | $ 953 | $ 1,740 |
Options | ||
Number | ||
Options granted (in shares) | 0 | |
Options exercised (in shares) | (15,112) | |
Options forfeited (in shares) | (58,894) | |
Options exercisable at the end of the period (in shares) | 1,081,735 | |
Average exercise price | ||
Options granted (in USD per share) | $ 0.00 | |
Options exercised (in USD per share) | 1.43 | |
Options forfeited (in USD per share) | 8.52 | |
Options exercisable at the end of the period (in USD per share) | $ 5.57 | |
Average remaining contractual life (in years) | ||
Options exercisable at the end of the period | 6 years 5 months 19 days | |
Aggregate intrinsic value (in thousands) | ||
Options exercisable at the end of the period | $ 495 | |
RSU | ||
Number | ||
RSUs granted (in shares) | 0 | |
RSUs vested (in shares) | (7,363) | |
RSUs forfeited (in shares) | (24,534) |
SHAREHOLDERS' EQUITY (Schedule of Options and RSUs Outstanding Which have been Separated into Ranges of Exercise Price) (Details) - $ / shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Dec. 31, 2016 |
|
RSU | ||
Ranges of Exercise Price [Line Items] | ||
RSUs outstanding (in shares) | 194,702 | |
Options | ||
Ranges of Exercise Price [Line Items] | ||
Options exercisable (in shares) | 1,081,735 | |
Options exercisable weighted average remaining contractual life (years) | 6 years 5 months 19 days | |
Stock Options and RSUs | ||
Ranges of Exercise Price [Line Items] | ||
Options outstanding weighted average remaining contractual life (years) | 7 years 4 months 10 days | |
Options and RSU's outstanding (in shares) | 2,145,111 | 2,251,014 |
$0.82 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 0.82 | |
Range of exercise price, maximum (in USD per share) | $ 0.82 | |
Options outstanding (in shares) | 34,377 | |
Options outstanding weighted average remaining contractual life (years) | 3 years 9 months 15 days | |
Options exercisable (in shares) | 34,377 | |
Options exercisable weighted average remaining contractual life (years) | 3 years 9 months 15 days | |
$1.32 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 1.32 | |
Range of exercise price, maximum (in USD per share) | $ 1.32 | |
Options outstanding (in shares) | 336,905 | |
Options outstanding weighted average remaining contractual life (years) | 5 years 1 month 6 days | |
Options exercisable (in shares) | 334,997 | |
Options exercisable weighted average remaining contractual life (years) | 5 years 1 month 2 days | |
$1.48 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 1.48 | |
Range of exercise price, maximum (in USD per share) | $ 1.48 | |
Options outstanding (in shares) | 384,323 | |
Options outstanding weighted average remaining contractual life (years) | 6 years 5 months 1 day | |
Options exercisable (in shares) | 307,132 | |
Options exercisable weighted average remaining contractual life (years) | 6 years 5 months 16 days | |
$6.80- $8.99 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 6.80 | |
Range of exercise price, maximum (in USD per share) | $ 8.99 | |
Options outstanding (in shares) | 720,618 | |
Options outstanding weighted average remaining contractual life (years) | 8 years 5 months 27 days | |
Options exercisable (in shares) | 240,800 | |
Options exercisable weighted average remaining contractual life (years) | 8 years 11 days | |
$9.22- $10.98 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 9.22 | |
Range of exercise price, maximum (in USD per share) | $ 10.98 | |
Options outstanding (in shares) | 220,056 | |
Options outstanding weighted average remaining contractual life (years) | 9 years 1 month 10 days | |
Options exercisable (in shares) | 14,558 | |
Options exercisable weighted average remaining contractual life (years) | 9 years 11 days | |
$19.62-$20.97 | Options | ||
Ranges of Exercise Price [Line Items] | ||
Range of exercise price- minimum (in USD per share) | $ 19.62 | |
Range of exercise price, maximum (in USD per share) | $ 20.97 | |
Options outstanding (in shares) | 254,130 | |
Options outstanding weighted average remaining contractual life (years) | 7 years 6 months 15 days | |
Options exercisable (in shares) | 149,871 | |
Options exercisable weighted average remaining contractual life (years) | 7 years 4 months 28 days |
SHAREHOLDER'S EQUITY (Share-based Awards to Non-Employee Consultants) (Details) |
3 Months Ended |
---|---|
Mar. 31, 2017
shares
| |
RSU | |
Share-based Goods and Nonemployee Services Transaction [Line Items] | |
RSUs granted (in shares) | 0 |
Non-employee Consultants | RSU | |
Share-based Goods and Nonemployee Services Transaction [Line Items] | |
RSUs granted (in shares) | 1,500 |
Non-employee Consultants | Nonemployee Options and RSUs | |
Share-based Goods and Nonemployee Services Transaction [Line Items] | |
Options and RSUs outstanding (in shares) | 0 |
SHAREHOLDER'S EQUITY (Schedule of Warrants) (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Dec. 28, 2016 |
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Class of Warrant or Right [Line Items] | |||
Drawdowns under loan agreement | $ 0 | $ 12,000 | |
Term Loan | 10.75% Term Loan Due January 2019 | |||
Class of Warrant or Right [Line Items] | |||
Drawdowns under loan agreement | $ 8,000 | ||
Ordinary Share | |||
Class of Warrant or Right [Line Items] | |||
Warrants outstanding (in shares) | 3,008,316 | ||
Warrants exercisable (in shares) | 3,008,316 | ||
Warrants to Purchase Ordinary Shares Issued on July 14, 2014 | |||
Class of Warrant or Right [Line Items] | |||
Warrants outstanding (in shares) | 403,804 | ||
Exercise price (in USD per share) | $ 10.08 | ||
Warrants exercisable (in shares) | 403,804 | ||
Warrants to Purchase Ordinary Shares Issued on December 30, 2015 | |||
Class of Warrant or Right [Line Items] | |||
Warrants outstanding (in shares) | 119,295 | ||
Exercise price (in USD per share) | $ 9.64 | ||
Warrants exercisable (in shares) | 119,295 | ||
Minimum percentage of acquired company required to prevent warrants from becoming exercisable | 50.00% | ||
November 1, 2016 | |||
Class of Warrant or Right [Line Items] | |||
Warrants outstanding (in shares) | 2,437,500 | ||
Exercise price (in USD per share) | $ 4.75 | ||
Warrants exercisable (in shares) | 2,437,500 | ||
December 28, 2016 | |||
Class of Warrant or Right [Line Items] | |||
Warrants outstanding (in shares) | 47,717 | ||
Exercise price (in USD per share) | $ 9.64 | ||
Warrants exercisable (in shares) | 47,717 | ||
Number of warrants issued (in shares) | 47,717 |
SHAREHOLDERS' EQUITY (Schedule of Non-cash Share-based Compensation Expense) (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | $ 851 | $ 717 |
Cost of revenues | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 28 | 22 |
Research and development, net | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 113 | 113 |
Sales and marketing, net | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | 185 | 174 |
General and administrative | ||
Non-cash share-based compensation expense [Line Items] | ||
Non-cash share-based compensation expense | $ 525 | $ 408 |
SHAREHOLDER'S EQUITY (Narrative- Share-based Compensation Expense for employees and non-employees) (Details) - USD ($) |
3 Months Ended | 11 Months Ended | 12 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Mar. 31, 2016 |
Mar. 31, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
May 10, 2016 |
||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||
Maximum amount which can be raised under ATM offering program | $ 25,000,000 | $ 25,000,000 | $ 25,000,000.0 | |||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Stock issuance costs under equity distribution agreement as a percent of gross proceeds | 3.00% | |||||||
Issuance expenses | 41,000 | |||||||
ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses | 699,000 | 5,300,000 | ||||||
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses | 611,000 | [1] | 4,700,000 | $ 4,099,000 | ||||
Underwriter commission, fees and offering expenses | $ 88,000 | $ 556,000 | ||||||
Piper Jaffray | ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Issuance expenses | $ 158,000 | |||||||
Maximum | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Stock issuance costs under equity distribution agreement as a percent of gross proceeds | 8.00% | |||||||
Weighted Average | ATM Offering Program | ||||||||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||||||||
Price per share of shares sold under ATM offering program (in USD per share) | $ 2.27 | $ 5.27 | ||||||
|
FINANCIAL EXPENSES, NET (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Other Income and Expenses [Abstract] | ||
Foreign currency transactions and other | $ (19) | $ 19 |
Financial expenses related to loan agreement with Kreos | 739 | 479 |
Bank commissions | 11 | 9 |
Income related to hedging transactions | 0 | (18) |
Financial expenses, net | $ 731 | $ 489 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Additional Information (Details) |
3 Months Ended |
---|---|
Mar. 31, 2017
segment
| |
Segment Reporting [Abstract] | |
Number of reportable segments | 1 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of revenues and long-lived assets by geographic region) (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Revenues | $ 2,499 | $ 2,061 | |
Long-lived assets | 1,117 | $ 1,258 | |
Israel | |||
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Revenues | 0 | 0 | |
Long-lived assets | 426 | 476 | |
United States | |||
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Revenues | 2,099 | 1,739 | |
Long-lived assets | 498 | 565 | |
Europe | |||
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Revenues | 400 | 260 | |
Asia-Pacific | |||
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Revenues | 0 | $ 62 | |
Germany | |||
Summary of revenues and long-lived assets by geographic region [Line items] | |||
Long-lived assets | $ 193 | $ 217 |
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of major customer data as a percentage of total revenues) (Details) |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2017 |
Dec. 31, 2016 |
|
Revenue | Customer concentration | Customer A | ||
Major customer data as a percentage of total revenues [Line items] | ||
Concentration risk (as a percent) | 61.00% | 33.00% |
,Y@)3FH) ^4""_)-@^2$$2(IP0 X5DOOE."4OBM3T,MR'_MTR /1M1# M[0 4RM'"ZX<6/ B%:@(30D$>+E+JJP%0>;K0+PCTJP>$0S7$5X.#/!\89\R7 M \ X10M=@V!W0R340WT])$@D2/"H0A#-EOH&=DH46J7PK7+$O"^:9-Q7 \'R M=*ES8+]$H6$*WS 1Y)B^& "SU#6P7Z+0,(5OF"-&O&^'U'<:$)9CO* 'MDTD M0CV9KV? Y/-$Z1WQ+1R&,9[./PM_
KBE>2X
M^_=+R8HL :!3/\2Z' ' 'G@<'S.BU_E7NO*^9TF63D9[:OJ>.^ZY7JOT[C\
MDA]U9MYL\R*-*W-;[-SR6.AXTQBEB0
M(NM9 ]_ ?N\OVEED8:FXA,YPU2$-=8X?-Z=SZO$!\(/#:%9[Y"NY*O7BC<]5
MCA.?$ @HK6=@;KG!$PCAB5P:OV9.O$CZP/7^C?UCJ-W5/.+P
M'8'$*9 X/$8SCSUF.?$8AC@-9K"= Q8D&ULE5?1;ILP%/T5Q <4;+"!*(D4DJ:;M$E5JVW/-'$25, 9.$GW][,-
MH8!O,I:'@,VYQ^=>+D?V],++]^K F+ ^\JRH9O9!B./$<:K-@>5)]<"/K)!/
M=KS,$R&'Y=ZICB5+MCHHSQSLNM3)D[2PYU,]]US.I_PDLK1@SZ55G?(\*?_$
M+..7F8WLZ\1+NC\(->',I\=DSUZ9^'%\+N7(:5FV:
SR_J/T)VE^5 #>P4?V6M[2O\@%$+'3UQ^ZS&GQ#SW&,4P_^&,W ']T[<
M&HWB)ORBYF2L$E'%61'T?1J9#.,8]2^T=4(6"=E,2(M/"7DDY L"F9R%J-^I
MI76IU8CT=%@#]7
"
M0V?]]*N;Z^FF3X550WS$9/XGJ?\#4$L#!!0 ( +))I$K(!& )_ $ .P%
M 9 >&PO=V]R:W-H965T
[7F$&-:JKK_D$T
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MVV8LX:))^[>T@L[NZ_1HUW\O^B7Y_4!?GX6U%<'MELOX74$L#!!0 (
M +))I$KT'W*N P( .8% 9 >&PO=V]R:W-H965T
)^MX0.(&3'2:- (B/_C_OU$ $]>X6K
3NKOBF+A1\G5VQ3J/5$@AD>R5'>"*@/!]6F2DWS>4K!;.UEDL(RP2
MLB?$:'T&=N[O: XYMN4Z) $:3E)M#I<9 10@PD1Q(FD3BB(I#H3:192!NEA/
M5"0NXH$BROIAYN%Z73@VIJ, P7'(Q]'N6> ED@KA@DF;L-$B>DB!6BA("P'3
MD@1QR&A\>+<>D'W<:/0 \"#E,88&P%[Z)1.)ZV551;C]>".',MES\XS'\52OTU*/-A:4."=1X<*N4.
M.[C3 @&="?H2O%"*6D%KEWF=1IJ-M*C3L_-[J@(249&.Z'5= ["D0KUDCY55ES:A2H(^!2AC$MJR:3W+>4]L@!*2E>_.QI^V^EW\:=S'PUF /M4
MQ)P@LS_XX5LS%(7Z8A(20=>)&'>'_
'EG=K80S_2_-5O>C>ED=Q$J@M^6X/P:&,A G!,\\
M M(R]?/4&4Z&\&MN"D.XC@